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Introduction {#jcsm12402-sec-0005}
============

Cancer cachexia is a recognized problem in the clinical setting of patients suffering from malignant cancer. It is well known to be associated with increased mortality[1](#jcsm12402-bib-0001){ref-type="ref"} and decreased well‐being of patients.[2](#jcsm12402-bib-0002){ref-type="ref"} Therapies to stop or even reverse the loss of body weight and muscle mass---which are the hallmarks of cancer cachexia---are lacking[3](#jcsm12402-bib-0003){ref-type="ref"}; hence, cancer cachexia is an area of unmet medical need and is hence of great research interest.[4](#jcsm12402-bib-0004){ref-type="ref"}

What is less known is that the prevalence of cancer cachexia is relatively low in the general population, compared to common afflictions. This is very relevant for today\'s research efforts because both the USA and the European Union (EU) have implemented special clinical development rules for what are called 'orphan diseases'. Thereby, both the USA and EU have promoted research into these fields and supported the development of new therapies for these relatively rare diseases. To our knowledge, published evidence has not been available examining whether cancer cachexia should be considered an orphan disease. Therefore, a significant discussion point in any such research context is the actual number of patients who might benefit from new treatment approaches. We therefore wish to address the question of whether cancer cachexia associated with various cancer types, complicating the major cancer subtypes prevalent in developed countries, could be classified as a collection of orphan diseases, based on the available evidence of the number of patients affected.

In the USA, with ca. 319 million inhabitants in 2014,[5](#jcsm12402-bib-0005){ref-type="ref"} any illness affecting less than 200 000 people is considered to be an orphan disease (as defined by the 'rare disease act of 2002').[6](#jcsm12402-bib-0006){ref-type="ref"} In the EU, presently consisting of 28 countries with ca. 505 million inhabitants in 2013,[7](#jcsm12402-bib-0007){ref-type="ref"} the limit to establish the presence of an orphan disease is 5 per 10 000 people (as defined by the European Medicines Agency)[8](#jcsm12402-bib-0008){ref-type="ref"}---amounting to a cut‐off at 255 000 people for the EU as a whole.

Methods and results {#jcsm12402-sec-0006}
===================

The aim of this analysis was to estimate the number of patients currently suffering in the USA and EU from cachexia complicating both the common cancer types and other specific cancer types where cachexia is known to be a frequent complication. We therefore needed three variables: (i) the prevalence of each cancer type, (ii) the percentage of such patients that are at risk to develop cachexia, and (iii) the prevalence of cachexia in all patients at risk (Figure [1](#jcsm12402-fig-0001){ref-type="fig"}).

![Formula for estimating the number of patients suffering from cancer cachexia.](JCSM-10-22-g001){#jcsm12402-fig-0001}

Prevalence of cancer entities {#jcsm12402-sec-0007}
-----------------------------

In oncologic research, most commonly the 5‐year prevalence is used to show the burden of different cancer entities. This is the number of patients who have developed any type of cancer in previous 5 years and who are still alive (at the time of assessment). At the same time, this number does not reveal whether the patient is still suffering from the condition or in fact has actually already been cured. Numbers for the total prevalence of individual cancer types (the proportion of the population with cancer at any time during their lifetime, or 'lifetime prevalence') are not published in EU, in an effort not to stigmatize patients that have been cured of cancer, but these data are available for the USA. These total prevalence data from the USA should be used with some caution, because an unknown proportion of these patients may have already been cured (or be in complete remission). To present the complete picture on both total and 5‐year prevalence for both regions, the latest available data for the USA from 2014 (Table [1](#jcsm12402-tbl-0001){ref-type="table"}, [9](#jcsm12402-bib-0009){ref-type="ref"}) were used to estimate the total prevalence estimates for the EU in 2013 in Table [2](#jcsm12402-tbl-0002){ref-type="table"},[9](#jcsm12402-bib-0009){ref-type="ref"}, [10](#jcsm12402-bib-0010){ref-type="ref"} using the same ratios that were observed between 5‐year prevalence and total prevalence in the USA, based on the working assumption that expected total prevalence rates between these two populations would be similar. In both tables, we analysed the top‐10 cancer types with the highest prevalence overall and four additional cancer types that are known to be frequently associated with cancer cachexia, namely, head and neck cancer, gastric cancer, liver cancer, and pancreatic cancer. The resulting 14 cancer types selected for analysis represent about 85% of all cancer cases.

###### 

Prevalence of cancer cachexia in the USA (2014)

  USA (2014)                       Prevalence of respective cancer   5‐year prevalence of respective cancer   5‐year survival rate (%) of respective cancer   Patients at risk to develop cachexia (%)   Patients at risk to develop cachexia (*n*)   Cancer cachexia prevalence in patients at risk (%)   Patients suffering from cancer cachexia in USA (2014)   Prevalence in USA per 10 000 people (2014)
  -------------------------------- --------------------------------- ---------------------------------------- ----------------------------------------------- ------------------------------------------ -------------------------------------------- ---------------------------------------------------- ------------------------------------------------------- --------------------------------------------
                                                                                                                                                                                                                                                                                                                                                                   
  All cancer patients              14 738 719                        4 811 335                                67                                              36.4                                       1 751 326                                    30.1                                                 527 100                                                 16.5
  Prostate cancer                  3 085 209                         1 038 106                                99                                              20                                         207 621                                      15.3                                                 31 800                                                  1.0
  Breast cancer                    3 346 387                         992 786                                  91                                              30                                         297 836                                      23.5                                                 70 000                                                  2.2
  Colorectal cancer                1 317 247                         446 441                                  66                                              50                                         223 221                                      31.8                                                 71 000                                                  2.2
  Melanoma of the skin             1 169 351                         343 875                                  94                                              20                                         68 775                                       22.1                                                 15 200                                                  0.5
  Endometrial cancer               710 228                           219 407                                  83                                              40                                         87 763                                       32.2                                                 28 300                                                  0.9
  Thyroid cancer                   726 646                           226 991                                  98                                              30                                         68 097                                       39.9                                                 27 200                                                  0.9
  Urinary bladder cancer           696 440                           258 861                                  78                                              30                                         77 658                                       25.2                                                 19 600                                                  0.6
  Non‐hodgkin lymphoma             661 996                           247 549                                  73                                              30                                         74 265                                       28.4                                                 21 100                                                  0.7
  Lung cancer                      527 228                           309 108                                  20                                              80                                         247 286                                      37.2                                                 92 000                                                  2.9
  Kidney and renal pelvis cancer   483 225                           197 821                                  75                                              40                                         79 128                                       31.6                                                 25 000                                                  0.8
  Head and neck cancer             446 816                           172 669                                  66                                              70                                         120 868                                      42.3                                                 51 100                                                  1.6
  Gastric cancer                   95 764                            48 271                                   31                                              70                                         33 790                                       33.3                                                 11 00                                                   0.4
  Liver cancer                     66 771                            47 284                                   19                                              90                                         42 556                                       50.1                                                 21 300                                                  0.7
  Pancreatic cancer                64 668                            48 921                                   9                                               90                                         44 029                                       45.6                                                 20 100                                                  0.6

###### 

Prevalence of cancer cachexia in the European Union (2013)

  European Union (2013)            Prevalence of respective cancer   5‐year prevalence of respective cancer   5‐year survival rate (%) of respective cancer   Patients at risk to develop cachexia (%)   Patients at risk to develop cachexia (*n*)   Cancer cachexia prevalence in patients at risk (%)   Patients suffering from cancer cachexia in Europe (2013)   Prevalence in Europe per 10 000 people (2013)
  -------------------------------- --------------------------------- ---------------------------------------- ----------------------------------------------- ------------------------------------------ -------------------------------------------- ---------------------------------------------------- ---------------------------------------------------------- -----------------------------------------------
                                                                                                                                                                                                                                                                                                                                                                      
  All cancer patients              21 734 000                        7 094 752                                67                                              37.6                                       2 667 627                                    30.0                                                 800 300                                                    15.8
  Breast cancer                    4 831 000                         1 433 147                                91                                              30                                         429 944                                      23.5                                                 *101 000*                                                  2.0
  Prostate cancer                  3 774 000                         1 269 716                                99                                              20                                         253 943                                      15.3                                                 *38 900*                                                   0.8
  Colorectal cancer                2 785 000                         943 864                                  66                                              50                                         471 932                                      31.8                                                 *150 100*                                                  3.0
  Urinary bladder cancer           1 103 000                         409 811                                  78                                              30                                         122 943                                      25.2                                                 *31 000*                                                   0.6
  Melanoma of the skin             1 100 000                         323 467                                  94                                              20                                         64 693                                       22.1                                                 *14 300*                                                   0.3
  Endometrial cancer               784 000                           242 071                                  83                                              40                                         96 828                                       32.2                                                 *31 200*                                                   0.6
  Head and neck cancer             749 000                           289 272                                  66                                              70                                         202 490                                      42.3                                                 *85 700*                                                   1.7
  Kidney and renal pelvis cancer   601 000                           246 231                                  75                                              40                                         98 492                                       31.6                                                 *31 100*                                                   0.6
  Lung cancer                      573 000                           336 143                                  20                                              80                                         268 914                                      37.2                                                 *100 000*                                                  2.0
  Non‐hodgkin lymphoma             563 000                           210 508                                  73                                              30                                         63 152                                       28.4                                                 *17 900*                                                   0.4
  Thyroid cancer                   469 000                           146 631                                  98                                              30                                         43 989                                       39.9                                                 *17 600*                                                   0.3
  Gastric cancer                   234 000                           117 782                                  31                                              70                                         82 447                                       33.3                                                 *27 500*                                                   0.5
  Liver cancer                     66 000                            46 478                                   19                                              90                                         41 830                                       50.1                                                 *21 000*                                                   0.4
  Pancreatic cancer                57 000                            43 197                                   9                                               90                                         38 877                                       45.6                                                 *17 700*                                                   0.4

Of the two prevalence estimates, total and 5 years, the more relevant 5‐year prevalence of each cancer type was used in the calculations described below. The 5‐year prevalence represents the ongoing burden of each cancer in the USA and EU more accurately and is less influenced by patients who are often considered cured after 5 years of follow‐up. In simple terms, this methodology estimates the prevalence of each cancer type after exclusion of likely long‐term survivors, thereby more accurately defining the population most likely to be at risk of cachexia.

Prevalence of cachexia {#jcsm12402-sec-0008}
----------------------

For this systematic review, we searched in PubMed to identify clinical studies that assessed the prevalence of cachexia in at least 50 cancer patients at risk, considering articles from inception to 31 January 2018 (Figure [2](#jcsm12402-fig-0002){ref-type="fig"}). Our search algorithm was defined as 'cachexia OR weight loss OR malnutrition AND (cancer OR prostate cancer OR breast cancer OR colorectal cancer OR melanoma OR endometrial cancer OR thyroid cancer OR urinary bladder cancer OR non‐hodgkin lymphoma OR lung cancer OR kidney and renal pelvis cancer OR head and neck cancer OR gastric cancer OR liver cancer OR pancreatic cancer) AND (frequency OR epidemiology OR prevalence OR estimate)'. We excluded all reviews, clinical trials, case reports, animal studies, studies in children aged \<18 years, not published in English, less than 50 patients, lacking data on cachexia, or weight loss prevalence in specific cancer entities. Studies reporting the prevalence of either *cachexia* or *wasting disease* in any of the top‐10 most prevalent cancer types plus 4 other selected cancer types known to be particularly often complicated by cachexia were screened and included in this analysis. Senior colleagues were interviewed to find additional relevant papers in areas were few or no reports of interest could be identified.

![Flow diagram of the study selection process.](JCSM-10-22-g002){#jcsm12402-fig-0002}

Altogether, we identified 21 studies published between 1980 and 2017 and reporting on 31 047 cancer patients as shown in Table [3](#jcsm12402-tbl-0003){ref-type="table"}.[11](#jcsm12402-bib-0011){ref-type="ref"}, [12](#jcsm12402-bib-0012){ref-type="ref"}, [13](#jcsm12402-bib-0013){ref-type="ref"}, [14](#jcsm12402-bib-0014){ref-type="ref"}, [15](#jcsm12402-bib-0015){ref-type="ref"}, [16](#jcsm12402-bib-0016){ref-type="ref"}, [17](#jcsm12402-bib-0017){ref-type="ref"}, [18](#jcsm12402-bib-0018){ref-type="ref"}, [19](#jcsm12402-bib-0019){ref-type="ref"}, [20](#jcsm12402-bib-0020){ref-type="ref"}, [21](#jcsm12402-bib-0021){ref-type="ref"}, [22](#jcsm12402-bib-0022){ref-type="ref"}, [23](#jcsm12402-bib-0023){ref-type="ref"}, [24](#jcsm12402-bib-0024){ref-type="ref"}, [25](#jcsm12402-bib-0025){ref-type="ref"}, [26](#jcsm12402-bib-0026){ref-type="ref"}, [27](#jcsm12402-bib-0027){ref-type="ref"}, [28](#jcsm12402-bib-0028){ref-type="ref"}, [29](#jcsm12402-bib-0029){ref-type="ref"}, [30](#jcsm12402-bib-0030){ref-type="ref"}, [31](#jcsm12402-bib-0031){ref-type="ref"} These studies provided acceptably reliable data for all of the 14 cancer entities selected for analysis. Depending on the diagnosis, results for 500 to 4900 patients were available. Only for melanoma were fewer patients reported upon, because cachexia in melanoma patients is rarely studied alone and is frequently reported only in a combined category with other less common cancer entities. The data found for melanoma patients were sufficient, however, for estimation purposes. The 21 studies each looked separately at one to nine cancer types. Studies that did not differentiate between different cancer types and their occurrence of cachexia were not considered for this analysis. It should be noted that the individual studies analysed had varying inclusion criteria for the diagnosis of cachexia ranging from weight loss of ≥1% to ≥10%. The consensus definition of cachexia by Evans *et al*.[32](#jcsm12402-bib-0032){ref-type="ref"} defined cachexia as a complex metabolic syndrome associated with the underlying illness. In alignment with the consensus definition, a weight loss of at least ≥5% is considered sufficient to diagnose cachexia. A low body mass index (\<20 or \<18.5) has also been used to define presence of cachexia, often in combination with weight loss of 2--5% or biochemical abnormalities.[33](#jcsm12402-bib-0033){ref-type="ref"} The data for the 31 047 patients shown in Table [3](#jcsm12402-tbl-0003){ref-type="table"} originate in the USA, EU, Australia, Canada, and Asia and therefore represent, it is believed, a broad cross section of cancer experience appropriate to characterize the diverse populations in the USA and EU. The proportions of patients in advanced tumour stages or with metastatic disease were generally high in these studies (up to 100% metastatic disease). The frequency of cachexia ranged from 11--74%.

###### 

Prevalence of cancer cachexia in all analysed studies

  **Cancer type**                                **Criteria for cachexia diagnosis**                                           **Tumour stage**      **Patient age (years)**  **Study type**                  **Date of study (years)**   **Number of patients**   **Cachexia frequency in patients (%)**  **Countries where data was developed**   **Reference**
  ---------------------------------------------- ----------------------------------------------------------------------------- -------------------- ------------------------- ------------------------------ --------------------------- ------------------------ ---------------------------------------- ---------------------------------------- ----------------------------------------------------------------
  Liver cancer                                   WL\>5% or BMI\<20 and WL 2‐5%                                                 88% UICC III/IV                63±13           observational study                      2012‐14                      25                               36                    Italy                                    Muscaritoli *et al*.[11](#jcsm12402-bib-0011){ref-type="ref"}
  Liver cancer                                   diagnosis, cachexia medication, WL≥5%                                         40% metastatic                 64±12           observational study                     1999‐2004                    156                               24                    USA                                      Fox *et al*.[17](#jcsm12402-bib-0017){ref-type="ref"}
  Liver cancer                                   BMI\<18.5, S‐Alb\<2.8 g/dL, TLC\<1200 cells/mm3                               64% UICC III/IV                30‐80           observational study                       2004                      1,497                              53                    South Korea                              Wie *et al*.[31](#jcsm12402-bib-0031){ref-type="ref"}
  Pancreatic cancer                              WL\>5% or BMI\<20 and WL 2‐5%                                                 86% UICC III/IV                63±13           observational study                      2012‐14                      94                               74                    Italy                                    Muscaritoli *et al*.[11](#jcsm12402-bib-0011){ref-type="ref"}
  Pancreatic cancer                              WL≥5% at time of operation                                                    40% UICC III/IV                57‐70           observational study                      2004‐05                     227                               41                    Germany                                  Bachmann *et al*.[12](#jcsm12402-bib-0012){ref-type="ref"}
  Pancreatic cancer                              diagnosis or BMI\<20 and/or WL≥5%                                             not reported                   63±12           observational study                      2002‐09                      60                               27                    Germany                                  Barkhudaryan *et al*.[13](#jcsm12402-bib-0013){ref-type="ref"}
  Pancreatic cancer                              WL≥5% in last six months                                                      not reported                   30‐80           observational study                      1976‐80                     111                               54                    USA                                      Dewys *et al*.[16](#jcsm12402-bib-0016){ref-type="ref"}
  Pancreatic cancer                              diagnosis, cachexia medication, WL≥5%                                         40% metastatic                 64±12           observational study                     1999‐2004                    221                               35                    USA                                      Fox *et al*.[17](#jcsm12402-bib-0017){ref-type="ref"}
  Pancreatic cancer                              BMI\<18.5 + \<75 yrs or BMI\<21 + ≥75 yrs and/or WL\>10%                      48% metastatic                 59±13           observational study                       2013                        42                               67                    France                                   Hébuterne *et al*.[19](#jcsm12402-bib-0019){ref-type="ref"}
  Lung cancer                                    WL\>5% or BMI\<20 and WL 2‐5%                                                 90% UICC III/IV                63±13           observational study                      2012‐14                     312                               43                    Italy                                    Muscaritoli *et al*.[11](#jcsm12402-bib-0011){ref-type="ref"}
  Lung cancer                                    diagnosis or BMI\<20 and/or WL≥5%                                             not reported                   63±12           observational study                      2002‐09                      58                               34                    Germany                                  Barkhudaryan *et al*.[13](#jcsm12402-bib-0013){ref-type="ref"}
  Lung cancer                                    diagnosis, cachexia medication, WL≥5%                                         40% metastatic                 64±12           observational study                     1999‐2004                   1,294                              31                    USA                                      Fox *et al*.[17](#jcsm12402-bib-0017){ref-type="ref"}
  Lung cancer                                    BMI\<18.5 + \<75 yrs or BMI\<21 + ≥75 yrs and/or WL\>10%                      66% metastatic                 59±13           observational study                       2013                       247                               45                    France                                   Hébuterne *et al*.[19](#jcsm12402-bib-0019){ref-type="ref"}
  Lung cancer                                    WL\>10%                                                                       100% UICC III/IV               43‐86           observational study                       1991                       100                               39                    USA                                      Krech *et al*.[24](#jcsm12402-bib-0024){ref-type="ref"}
  Lung cancer                                    WL≥10%                                                                        81% metastatic                 59±14           observational study                      2007‐08                      90                               30                    France                                   Pressoir *et al*.[26](#jcsm12402-bib-0026){ref-type="ref"}
  Lung cancer                                    BMI\<18.5, S‐Alb\<2.8 g/dL, TLC\<1200 cells/mm3                               64% UICC III/IV                30‐80           observational study                       2004                      1,802                              41                    South Korea                              Wie *et al*.[31](#jcsm12402-bib-0031){ref-type="ref"}
  Lung cancer, non‐small cell                    WL≥5% in last six months                                                      not reported                   30‐80           observational study                      1976‐80                     590                               36                    USA                                      Dewys *et al*.[16](#jcsm12402-bib-0016){ref-type="ref"}
  Lung cancer, small cell                        WL≥5% in last six months                                                      not reported                   30‐80           observational study                      1976‐80                     436                               34                    USA                                      Dewys *et al*.[16](#jcsm12402-bib-0016){ref-type="ref"}
  Head and neck cancer                           WL\>5% or BMI\<20 and WL 2‐5%                                                 81% UICC III/IV                63±13           observational study                      2012‐14                      62                               39                    Italy                                    Muscaritoli *et al*.[11](#jcsm12402-bib-0011){ref-type="ref"}
  Head and neck cancer                           diagnosis, cachexia medication, WL≥5%                                         40% metastatic                 64±12           observational study                     1999‐2004                    249                               37                    USA                                      Fox *et al*.[17](#jcsm12402-bib-0017){ref-type="ref"}
  Head and neck cancer                           BMI\<18.5 + \<75 yrs or BMI\<21 + ≥75 yrs and/or WL\>10%                      11% metastatic                 59±13           observational study                       2013                       366                               49                    France                                   Hébuterne *et al*.[19](#jcsm12402-bib-0019){ref-type="ref"}
  Head and neck cancer                           WL≥10%                                                                        24% metastatic                 59±14           observational study                      2007‐08                     179                               37                    France                                   Pressoir *et al*.[26](#jcsm12402-bib-0026){ref-type="ref"}
  Gastric cancer                                 WL\>5% or BMI\<20 and WL 2‐5%                                                 80% UICC III/IV                63±13           observational study                      2012‐14                     108                               69                    Italy                                    Muscaritoli *et al*.[11](#jcsm12402-bib-0011){ref-type="ref"}
  Gastric cancer                                 WL≥5% in last six months                                                      not reported                   30‐80           observational study                      1976‐80                     317                               39                    USA                                      Dewys *et al*.[16](#jcsm12402-bib-0016){ref-type="ref"}
  Gastric cancer                                 diagnosis, cachexia medication, WL≥5%                                         40% metastatic                 64±12           observational study                     1999‐2004                    144                               41                    USA                                      Fox *et al*.[17](#jcsm12402-bib-0017){ref-type="ref"}
  Gastric cancer                                 BMI\<18.5, S‐Alb\<2.8 g/dL, TLC\<1200 cells/mm3                               64% UICC III/IV                30‐80           observational study                       2004                      2,069                              30                    South Korea                              Wie *et al*.[31](#jcsm12402-bib-0031){ref-type="ref"}
  Colorectal cancer                              WL\>5% or BMI\<20 and WL 2‐5%                                                 80% UICC III/IV                63±13           observational study                      2012‐14                     318                               60                    Italy                                    Muscaritoli *et al*.[11](#jcsm12402-bib-0011){ref-type="ref"}
  Colorectal cancer                              diagnosis or BMI\<20 and/or WL≥5%                                             not reported                   63±12           observational study                      2002‐09                      59                               31                    Germany                                  Barkhudaryan *et al*.[13](#jcsm12402-bib-0013){ref-type="ref"}
  Colorectal cancer                              WL≥5% in last six months                                                      not reported                   30‐80           observational study                      1976‐80                     307                               28                    USA                                      Dewys *et al*.[16](#jcsm12402-bib-0016){ref-type="ref"}
  Colorectal cancer                              diagnosis, cachexia medication, WL≥5%                                         40% metastatic                 64±12           observational study                     1999‐2004                    907                               25                    USA                                      Fox *et al*.[17](#jcsm12402-bib-0017){ref-type="ref"}
  Colorectal cancer                              BMI\<18.5 + \<75 yrs or BMI\<21 + ≥75 yrs and/or WL\>10%                      69% metastatic                 59±13           observational study                       2013                       191                               39                    France                                   Hébuterne *et al*.[19](#jcsm12402-bib-0019){ref-type="ref"}
  Colorectal cancer                              WL≥10%                                                                        64% metastatic                 59±14           observational study                      2007‐08                     156                               23                    France                                   Pressoir *et al*.[26](#jcsm12402-bib-0026){ref-type="ref"}
  Colorectal cancer                              BMI\<18.5, S‐Alb\<2.8 g/dL, TLC\<1200 cells/mm3                               64% UICC III/IV                30‐80           observational study                       2004                      1,778                              31                    South Korea                              Wie *et al*.[31](#jcsm12402-bib-0031){ref-type="ref"}
  Endometrial cancer                             BMI\<18.5 + \<75 yrs or BMI\<21 + ≥75 yrs and/or WL\>10%                      57% metastatic                 59±13           observational study                       2013                        87                               41                    France                                   Hébuterne *et al*.[19](#jcsm12402-bib-0019){ref-type="ref"}
  Endometrial cancer                             BMI\<18.5                                                                     45% UICC III/IV                53±12           observational study                       2013                       129                               11                    South Korea                              Nho *et al*. [25](#jcsm12402-bib-0025){ref-type="ref"}
  Endometrial cancer                             WL≥10%                                                                        61% metastatic                 59±14           observational study                      2007‐08                     137                               28                    France                                   Pressoir *et al*.[26](#jcsm12402-bib-0026){ref-type="ref"}
  Endometrial cancer                             BMI\<18.5, S‐Alb\<2.8 g/dL, TLC\<1200 cells/mm3                               64% UICC III/IV                30‐80           observational study                       2004                       927                               35                    South Korea                              Wie *et al*.[31](#jcsm12402-bib-0031){ref-type="ref"}
  renal cell carcinoma                           WL of \>2.26 kg in the last 3 months, S‐Alb\<3.6 g/dL, anorexia, or malaise   43% metastatic                 30‐80           observational study                     1989‐2001                   1,046                              35                    USA                                      Kim *et al*.[22](#jcsm12402-bib-0022){ref-type="ref"}
  renal cell carcinoma                           WL of \>2.26 kg in the last 3 months, S‐Alb\<3.6 g/dL, anorexia, or malaise   0% UICC III/IV                 63±12           observational study                     1989‐2001                    250                               15                    USA                                      Kim *et al*.[23](#jcsm12402-bib-0023){ref-type="ref"}
  Urogenital cancer                              WL\>5% or BMI\<20 and WL 2‐5%                                                 62% UICC III/IV                63±13           observational study                      2012‐14                     346                               30                    Italy                                    Muscaritoli *et al*.[11](#jcsm12402-bib-0011){ref-type="ref"}
  Urogenital cancer                              BMI≥28 and WL≥11% or BMI 20‐27.9 + WL ≥6% or BMI\<20                          85% metastatic                 57‐74           observational study                      2011‐13                     160                               39                    EU, Australia, Canada                    Vagnildhaug *et al*.[30](#jcsm12402-bib-0030){ref-type="ref"}
  Urinary bladder cancer                         BMI\<18.5, S‐Alb\<3.5 g/dL, or WL\>5%                                         44% UICC III/IV                68±10           observational study                      2000‐08                     538                               19                    USA                                      Gregg *et al*.[18](#jcsm12402-bib-0018){ref-type="ref"}
  Urinary bladder cancer                         S‐Alb\<3.5 g/dL, or WL\>5%                                                    not reported                   66±10           observational study                     1991‐2002                   2,538                              25                    USA                                      Hollenbeck *et al*.[20](#jcsm12402-bib-0020){ref-type="ref"}
  Unfavorable Non‐Hodgkin Lymphoma               WL≥5% in last six months                                                      not reported                   30‐80           observational study                      1976‐80                     311                               28                    USA                                      Dewys *et al*.[16](#jcsm12402-bib-0016){ref-type="ref"}
  Unfavorable Non‐Hodgkin Lymphoma               derived from muscle mass, albumin, neutrophils, lymphozytes                   63% advanced stage             30‐80           observational study                     1991‐2015                     86                               47                    USA                                      Karmali *et al*.[21](#jcsm12402-bib-0021){ref-type="ref"}
  Favorable Non‐Hodgkin Lymphoma                 WL≥5% in last six months                                                      not reported                   30‐80           observational study                      1976‐80                     290                               18                    USA                                      Dewys *et al*.[16](#jcsm12402-bib-0016){ref-type="ref"}
  Leukemia, Lymphoma, Myeloma                    WL≥10%                                                                        16% metastatic                 59±14           observational study                      2007‐08                     156                               25                    France                                   Pressoir *et al*.[26](#jcsm12402-bib-0026){ref-type="ref"}
  Leukemia, Lymphoma                             BMI\<18.5 + \<75 yrs or BMI\<21 + ≥75 yrs and/or WL\>10%                      37% metastatic                 59±13           observational study                       2013                       377                               34                    France                                   Hébuterne *et al*.[19](#jcsm12402-bib-0019){ref-type="ref"}
  Thyroid cancer                                 WL≥5%                                                                         100% metastatic                34‐77           single‐arm phase II trial                2008‐10                      58                               69                    USA                                      Cabanillas *et al*.[15](#jcsm12402-bib-0015){ref-type="ref"}
  Thyroid cancer                                 WL≥5%                                                                         96% metastatic                 41‐81           single‐arm phase II trial                2013‐15                      25                               60                    USA                                      Cabanillas *et al*.[14](#jcsm12402-bib-0014){ref-type="ref"}
  Thyroid cancer                                 WL≥5%                                                                         100% metastatic                30‐80           randomized, controlled trial             2011‐12                     392                               34                    USA, EU, Asia, Australia                 Schlumberger *et al*.[27](#jcsm12402-bib-0027){ref-type="ref"}
  Thyroid cancer                                 WL≥5%                                                                         100% metastatic                22‐74           single‐arm phase II trial                2008‐10                      59                               42                    USA, EU, Australia                       Schlumberger *et al*.[28](#jcsm12402-bib-0028){ref-type="ref"}
  Breast cancer                                  WL\>5% or BMI\<20 and WL 2‐5%                                                 35% UICC III/IV                63±13           observational study                      2012‐14                     431                               14                    Italy                                    Muscaritoli *et al*.[11](#jcsm12402-bib-0011){ref-type="ref"}
  Breast cancer                                  WL≥5% in last six months                                                      not reported                   30‐80           observational study                      1976‐80                     289                               14                    USA                                      Dewys *et al*.[16](#jcsm12402-bib-0016){ref-type="ref"}
  Breast cancer                                  diagnosis, cachexia medication, WL≥5%                                         40% metastatic                 64±12           observational study                     1999‐2004                   2,112                              25                    USA                                      Fox *et al*.[17](#jcsm12402-bib-0017){ref-type="ref"}
  Breast cancer                                  BMI\<18.5 + \<75 yrs or BMI\<21 + ≥75 yrs and/or WL\>10%                      45% metastatic                 59±13           observational study                       2013                       229                               21                    France                                   Hébuterne *et al*.[19](#jcsm12402-bib-0019){ref-type="ref"}
  Breast cancer                                  WL≥10%                                                                        44% metastatic                 59±14           observational study                      2007‐08                     375                               12                    France                                   Pressoir *et al*.[26](#jcsm12402-bib-0026){ref-type="ref"}
  Breast cancer                                  BMI≥28 and WL≥11% or BMI 20‐27.9 + WL ≥6% or BMI\<20                          85% metastatic                 57‐74           observational study                      2011‐13                     252                               24                    EU, Australia, Canada                    Vagnildhaug *et al*.[30](#jcsm12402-bib-0030){ref-type="ref"}
  Breast cancer                                  BMI\<18.5, S‐Alb\<2.8 g/dL, TLC\<1200 cells/mm3                               64% UICC III/IV                30‐80           observational study                       2004                       877                               33                    South Korea                              Wie *et al*.[31](#jcsm12402-bib-0031){ref-type="ref"}
  Melanoma                                       WL\>10%                                                                       100% UICC III/IV               22‐59           observational study                       1982                        7                                14                    Netherlands                              Smit *et al*.[29](#jcsm12402-bib-0029){ref-type="ref"}
  Melanoma, prostate and others\*                WL≥10%                                                                        51% metastatic                 59±14           observational study                      2007‐08                     349                               19                    France                                   Pressoir *et al*.[26](#jcsm12402-bib-0026){ref-type="ref"}
  melanoma, Haematologic cancer and others\*\*   WL\>5% or BMI\<20 and WL 2‐5%                                                 52% UICC III/IV                63±13           observational study                      2012‐14                     141                               30                    Italy                                    Muscaritoli *et al*.[11](#jcsm12402-bib-0011){ref-type="ref"}
  Prostate cancer                                WL≥5% in last six months                                                      not reported                   30‐80           observational study                      1976‐80                      78                               28                    USA                                      Dewys *et al*.[16](#jcsm12402-bib-0016){ref-type="ref"}
  Prostate cancer                                diagnosis, cachexia medication, WL≥5%                                         40% metastatic                 64±12           observational study                     1999‐2004                   3,351                              15                    USA                                      Fox *et al*.[17](#jcsm12402-bib-0017){ref-type="ref"}
  Prostate cancer                                BMI\<18.5 + \<75 yrs or BMI\<21 + ≥75 yrs and/or WL\>10%                      38% metastatic                 59±13           observational study                       2013                        72                               14                    France                                   Hébuterne *et al*.[19](#jcsm12402-bib-0019){ref-type="ref"}

The average prevalence of cachexia in each cancer diagnosis was calculated by taking into account all patients with that diagnosis (Table [4](#jcsm12402-tbl-0004){ref-type="table"}). The data were not weighted based on the origin of patients (continent, country, etc.) and so, lacking a consensus standard for the diagnosis, represent a middle ground reflecting actual practice.

###### 

Frequency of cancer cachexia and of patients at risk to develop cachexia

  Cancer type (n, 5‐year survival rate)                Estimated cancer cachexia prevalence in patients at risk (%)   Patients at risk to develop cachexia (%)
  ---------------------------------------------------- -------------------------------------------------------------- ------------------------------------------
  Very high risk group---5‐year survival rate 0--30%                                                                  
  Liver cancer (1 678, 19%)                            50.1                                                           90
  Pancreatic cancer (755, 9%)                          45.6                                                           90
  Lung cancer (4 929, 20%)                             37.2                                                           80
  High risk group---5‐year survival rate 31--66%                                                                      
  Head and neck cancer (856, 66%)                      42.3                                                           70
  Gastric cancer (2 638, 31%)                          33.3                                                           70
  Colorectal cancer (3 716, 66%)                       31.8                                                           50
  Middle risk group---5‐year survival rate 67--90%                                                                    
  Endometrial cancer (1 280, 83%)                      32.2                                                           40
  Kidney and renal pelvis cancer (1 549, 75%)          31.6                                                           40
  Non‐hodgkin lymphoma (1 220, 73%)                    28.4                                                           30
  Urinary bladder cancer (3 329, 78%)                  25.2                                                           30
  Lower risk group---5‐year survival rate 91--100%                                                                    
  Thyroid cancer (534, 98%)                            39.9                                                           30
  Breast cancer (4 565, 91%)                           23.5                                                           30
  Melanoma of the skin (\<500, 94%)                    22.1                                                           20
  Prostate cancer (3 501, 99%)                         15.3                                                           20

During the literature research, we also found 10 clinical studies in 4312 patients that asked patients whether they ever lost any weight during the course of their disease. We are showing this data in Table [5](#jcsm12402-tbl-0005){ref-type="table"}, [34](#jcsm12402-bib-0034){ref-type="ref"}, [35](#jcsm12402-bib-0035){ref-type="ref"}, [36](#jcsm12402-bib-0036){ref-type="ref"}, [37](#jcsm12402-bib-0037){ref-type="ref"}, [38](#jcsm12402-bib-0038){ref-type="ref"}, [39](#jcsm12402-bib-0039){ref-type="ref"}, [40](#jcsm12402-bib-0040){ref-type="ref"}, [41](#jcsm12402-bib-0041){ref-type="ref"}, [42](#jcsm12402-bib-0042){ref-type="ref"}, [43](#jcsm12402-bib-0043){ref-type="ref"} but did not include it in our analysis, because the inclusion criteria were not sufficient to diagnose cachexia.

###### 

Studies reporting weight loss ≥1% as a categorical variable(Note: Weight loss ≥1% without further details was not considered sufficient for the diagnosis of cachexia)

  Cancer type            Criteria for weight loss                Tumour stage           Patient age range (years)  Study type             Date of study (years)   Number of patients   Frequency of any weight loss in all patients (%)  Countries where data were developed   Reference
  ---------------------- --------------------------------------- --------------------- --------------------------- --------------------- ----------------------- -------------------- -------------------------------------------------- ------------------------------------- -------------------------------------------------------------
  Endometrial cancer     any WL                                  100% UICC III/IV                30--80            observational study          1990--91                  83                                  22                         EU, USA, Australia                    Vainio *et al*.[42](#jcsm12402-bib-0042){ref-type="ref"}
  Endometrial cancer     any WL                                  100% UICC III/IV                21--80            observational study          1981--83                  74                                  84                         USA                                   Wachtel *et al*.[43](#jcsm12402-bib-0043){ref-type="ref"}
  Breast cancer          any WL in last week                     63% metastatic                  23--86            observational study          1990--92                  70                                  31                         USA                                   Portenoy *et al*.[39](#jcsm12402-bib-0039){ref-type="ref"}
  Breast cancer          any WL                                  100% UICC III/IV                15--82            observational study            1992                    44                                  88                         India                                 Sebastian *et al*.[40](#jcsm12402-bib-0040){ref-type="ref"}
  Breast cancer          any WL                                  100% UICC III/IV                30--80            observational study          1990--91                 186                                  22                         EU, USA, Australia                    Vainio *et al*.[42](#jcsm12402-bib-0042){ref-type="ref"}
  Breast cancer          any WL in last two weeks                56% metastatic                  19--92            observational study          2001--02                 101                                  28                         Spain                                 Segura *et al*.[41](#jcsm12402-bib-0041){ref-type="ref"}
  Breast cancer          any WL                                  100% UICC III/IV                21--80            observational study          1981--83                 127                                  78                         USA                                   Wachtel *et al*.[43](#jcsm12402-bib-0043){ref-type="ref"}
  Colorectal cancer      any WL in last week                     63% metastatic                  23--86            observational study          1990--92                  60                                  27                         USA                                   Portenoy *et al*.[39](#jcsm12402-bib-0039){ref-type="ref"}
  Colorectal cancer      any WL                                  100% UICC III/IV                30--80            observational study          1990--91                 127                                  53                         EU, USA, Australia                    Vainio *et al*.[42](#jcsm12402-bib-0042){ref-type="ref"}
  Colorectal cancer      any WL in last two weeks                56% metastatic                  19--92            observational study          2001--02                 103                                  32                         Spain                                 Segura *et al*.[41](#jcsm12402-bib-0041){ref-type="ref"}
  Colorectal cancer      any WL                                  100% UICC III/IV                21--80            observational study          1981--83                 148                                  81                         USA                                   Wachtel *et al*.[43](#jcsm12402-bib-0043){ref-type="ref"}
  Colorectal cancer      any WL before commencing chemotherapy   100% UICC III/IV                16--84            observational study          1990--96                 781                                  34                         UK                                    Andreyev *et al*.[34](#jcsm12402-bib-0034){ref-type="ref"}
  Lung cancer            any WL                                  100% UICC III/IV                15--82            observational study            1992                    10                                  80                         India                                 Sebastian *et al*.[40](#jcsm12402-bib-0040){ref-type="ref"}
  Lung cancer            any WL                                  100% UICC III/IV                30--80            observational study          1990--91                 387                                  49                         EU, USA, Australia                    Vainio *et al*.[42](#jcsm12402-bib-0042){ref-type="ref"}
  Lung cancer            any WL in last two weeks                56% metastatic                  19--92            observational study          2001--02                 179                                  36                         Spain                                 Segura *et al*.[41](#jcsm12402-bib-0041){ref-type="ref"}
  Lung cancer            any WL                                  100% UICC III/IV                21--80            observational study          1981--83                 288                                  83                         USA                                   Wachtel *et al*.[43](#jcsm12402-bib-0043){ref-type="ref"}
  Prostate cancer        any WL in last week                     63% metastatic                  23--86            observational study          1990--92                  63                                  25                         USA                                   Portenoy *et al*.[39](#jcsm12402-bib-0039){ref-type="ref"}
  Prostate cancer        any WL                                  100% UICC III/IV                30--80            observational study          1990--91                  78                                  26                         EU, USA, Australia                    Vainio *et al*.[42](#jcsm12402-bib-0042){ref-type="ref"}
  Prostate cancer        any WL                                  100% UICC III/IV                21--80            observational study          1981--83                  73                                  86                         USA                                   Wachtel *et al*.[43](#jcsm12402-bib-0043){ref-type="ref"}
  Lymphoma               any WL                                  100% advanced stage             30--80            observational study          1990--91                  67                                  33                         EU, USA, Australia                    Vainio *et al*.[42](#jcsm12402-bib-0042){ref-type="ref"}
  Pancreatic cancer      any WL                                  64% metastatic                  30--80            observational study            1990                    39                                  51                         USA                                   Krech *et al*.[37](#jcsm12402-bib-0037){ref-type="ref"}
  Pancreatic cancer      any WL                                  100% UICC III/IV                21--80            observational study          1981--83                  63                                  89                         USA                                   Wachtel *et al*.[43](#jcsm12402-bib-0043){ref-type="ref"}
  Pancreatic cancer      any WL before commencing chemotherapy   100% UICC III/IV                16--84            observational study          1990--96                 162                                  72                         UK                                    Andreyev *et al*.[34](#jcsm12402-bib-0034){ref-type="ref"}
  Head and neck cancer   any WL before commencing radiotherapy   not reported                    32--89            observational study            1989                   100                                  57                         UK                                    Lees *et al*.[38](#jcsm12402-bib-0038){ref-type="ref"}
  Head and neck cancer   any WL                                  100% UICC III/IV                15--82            observational study            1992                   175                                  97                         India                                 Sebastian *et al*.[40](#jcsm12402-bib-0040){ref-type="ref"}
  Head and neck cancer   any WL                                  100% UICC III/IV                30--80            observational study          1990--91                  94                                  33                         EU, USA, Australia                    Vainio *et al*.[42](#jcsm12402-bib-0042){ref-type="ref"}
  Head and neck cancer   any WL                                  100% UICC III/IV                41--87            observational study          1990--93                  38                                  79                         UK                                    Forbes *et al*.[36](#jcsm12402-bib-0036){ref-type="ref"}
  Gastric cancer         any WL before commencing chemotherapy   100% UICC III/IV                16--84            observational study          1990--96                 433                                  67                         UK                                    Andreyev *et al*.[34](#jcsm12402-bib-0034){ref-type="ref"}
  Gastric cancer         any WL                                  100% UICC III/IV                30--80            observational study          1990--91                  95                                  45                         EU, USA, Australia                    Vainio *et al*.[42](#jcsm12402-bib-0042){ref-type="ref"}
  Gastric cancer         any WL in last two weeks                56% metastatic                  19--92            observational study          2001--02                  34                                  50                         Spain                                 Segura *et al*.[41](#jcsm12402-bib-0041){ref-type="ref"}
  Bladder cancer         any WL in the last 6 weeks              53% UICC III/IV                 62 ± 7            observational study            1985                    30                                  30                         Denmark                               Enig *et al*.[35](#jcsm12402-bib-0035){ref-type="ref"}

WL, weight loss; UICC, Union Internationale contre le Cancer tumor stage; USA, United States of America; UK, United Kingdom.

Patients at risk {#jcsm12402-sec-0009}
----------------

For calculation of the patients at risk in each diagnosis, we categorized Table [4](#jcsm12402-tbl-0004){ref-type="table"} into four groups of very high, high, middle, and lower risk of cancer cachexia by taking into account the respective 5‐year survival rates of the cancer entities. Based on prior clinical experience that the intensity and progression of the cancer disease process is directly related to metabolic disorders responsible for cachexia, it has been assumed that patients with lower 5‐year survival rates are more prone to develop cachexia, and therefore, they have been classified as having a higher risk for cachexia development.

Because the 5‐year prevalence for each cancer takes into account the cured and sick patients alike, we had to consider this in our analysis and therefore estimated the actual patients at risk to develop cachexia with the help of these four risk groups. To the very high‐risk group, we attributed that 80--90% of the patients are at risk, in the high‐risk group 50--70%, in the middle‐risk group 30--40%, and in the lower‐risk group 20--30% (Table [4](#jcsm12402-tbl-0004){ref-type="table"}). Within the four risk groups, we considered the prevalence of cachexia in the patients at risk and again the 5‐year survival rate. We were therefore able to weigh the data within these groups (Table [4](#jcsm12402-tbl-0004){ref-type="table"}). Consequently, in the very high‐risk group, pancreatic cancer patients had the lowest 5‐year survival rate and liver cancer the highest prevalence of cachexia in patients at risk. We therefore attributed to both diagnoses that 90% of patients are at risk. Lung cancer had a higher 5‐year survival rate and lower cachexia prevalence in patients at risk within this very high‐risk group, and so we attributed that 80% of the patients are at risk to develop cachexia. We did the same for the other risk groups as well (Table [4](#jcsm12402-tbl-0004){ref-type="table"}).

Number of patients with cancer cachexia {#jcsm12402-sec-0010}
---------------------------------------

With the attained data, we were able to calculate the estimates for the numbers of cancer patients likely to be suffering from cancer cachexia in the USA (Table [1](#jcsm12402-tbl-0001){ref-type="table"}, Figure [3](#jcsm12402-fig-0003){ref-type="fig"}) and in the EU (Table [2](#jcsm12402-tbl-0002){ref-type="table"}, Figure [4](#jcsm12402-fig-0004){ref-type="fig"}). We estimate that in 2014, in the USA, 527 100 patients suffered from cancer cachexia (of any kind), equalling 16.5 subjects per 10 000 of the total population (USA inhabitants 2014: 318 622 530[5](#jcsm12402-bib-0005){ref-type="ref"}). In 2013, in the EU, a total of 800 300 patients suffered from cancer cachexia (of any kind), equalling 15.8 subjects per 10 000 people of the general population (EU inhabitants 2013: 505 170 000[7](#jcsm12402-bib-0007){ref-type="ref"}). For each specific cancer type, the absolute numbers of patients suffering of cachexia were lower than 200 000 patients in the USA, or less than 5 per 10 000 people in the EU, and for most types, substantially below those thresholds. Even if a high margin of error of ±30% is applied to the final results, cancer cachexia remains an orphan disease if each cancer type is considered separately, and this was true for all the specific cancer types studied. Given the wide variation in the risk of developing cachexia, we believe it is sensible to look at cancer‐specific cachexia rather than considering all cancer cachexia as a single disease.

![Prevalence of cancer cachexia in the USA (2014) with ±30% error bars to indicate the estimated uncertainty of the estimates.](JCSM-10-22-g003){#jcsm12402-fig-0003}

![Prevalence of cancer cachexia in the European Union (2013) with ±30% error bars to indicate the estimated uncertainty of the estimates.](JCSM-10-22-g004){#jcsm12402-fig-0004}

Discussion {#jcsm12402-sec-0011}
==========

The estimation of the prevalence of cachexia in cancer involves both epidemiological and clinical considerations, requiring both extensive research for current relevant data on multiple cancer types and the development of an approach to integrate that data into meaningful information. Those challenges may be responsible for the lack of published reports on the disease‐specific prevalence of cancer cachexia in the USA and EU populations.

Recently, Baracos *et al*.[44](#jcsm12402-bib-0044){ref-type="ref"} provided data on the prevalence of cachexia in eight cancer diagnoses considering information provided in two original studies with a total of about 3000 patients. In the present study, however, we used data from 21 original reports with a total of over 31 000 patients and assessed 14 cancer diagnoses---the 10 most frequent cancer diagnoses and another 4 cancer types that are frequently associated with cancer cachexia. Furthermore, we calculated the prevalence of cancer cachexia in the general population, giving one the chance to evaluate, whether individual disease related cancer cachexia syndromes should be considered orphan diseases in the USA or EU. We make the case that different cachexia disease types, potentially require individually targeted therapies. Currently, the National Cancer Institute identifies more than 200 different targeted drugs approved to treat over 100 separate cancer types separately.[45](#jcsm12402-bib-0045){ref-type="ref"}

Cancer cachexia (in different cancers) is not one and the same general disease. Underlying pathophysiology, genetics, and biochemistry, but also symptoms and prognostic importance are different[46](#jcsm12402-bib-0046){ref-type="ref"}---both in absolute terms and in their relative impact on disease progression and the patient burden---which is relevant for the development of novel treatment and prevention strategies. Research to this end is only in its infancy. Antecedent cancers are genomically distinct and have unique characteristics associated with the primary tissue affect, thus generally requiring individualized management efforts. Hence, it is reasonable that orphan disease status for cancer cachexia is assessed on the individual cancer type level and not for all cancer cachexia types together.

In the only available original research article on this issue, it has been estimated that cachexia is the immediate or primary cause of death in approximately 30% of cancer patients.[47](#jcsm12402-bib-0047){ref-type="ref"} Cancer cachexia is also associated with increased length of hospital stay as well as increased overall treatment costs.[48](#jcsm12402-bib-0048){ref-type="ref"} The possible ways how cachexia can cause death have been the subject of prior publications, which have concluded that in addition to cachexia interfering in the treatment of the cancer itself, it also acts as an indirect contributor to mortality.[49](#jcsm12402-bib-0049){ref-type="ref"} Future orphan treatments for cachexia might be divided into those that address symptoms and quality of life (palliative) and those that possibly impact mortality (directly addressing the life‐limiting disease).

Limitations {#jcsm12402-sec-0012}
-----------

We only have access to summaries of research based on individual patient series, and we therefore had to base our analyses on these data as published. These have somewhat varying definitions of cachexia, so that there is inherent uncertainty around our prevalence estimates. We believe that these variations are likely to be less than 20% above or below our central estimate. Even though we included \>30 000 patients in this analysis, which is more than ever shown before, the analysis summarizes only 21 studies, which is due to lack of attention of medicine and frustration about not being able to treat cachexia yet.

We used the 5‐year prevalence of each cancer type. This estimate is lower than the actual number of all people who ever had the cancer type and who still survive (by excluding those who have carried the diagnosis for more than 5 years). This may be thought to therefore slightly underestimate the prevalence of the respective cancer‐type‐specific cachexia, but the effect is likely to be small for two reasons. Patients who have survived more than 5 years include those with cured cancer and those with very slowly progressing disease. These patients will have a lower rate of cachexia development than all comers for that particular cancer type.The cancer patient who develops cachexia has a significantly worse survival than one who does not; therefore, the 5‐year prevalence data will have 'lost' some cachexia patients who have on average died earlier. This effect will therefore tend to overestimate the prevalence of cancer cachexia at any point in time, because we have used a constant risk of cachexia development for each cancer type whereas the 5‐year prevalence data for each cancer type contains an under‐representation of cachexia sufferers who have died and hence are no longer there to be counted in the 5‐year prevalence data.

For these reasons, we believe our estimates may actually overestimate rather than underestimate the prevalence of cancer‐type‐specific cachexia in the USA and in the EU and therefore the risk of misclassifying a condition as an orphan disease when it is not is low. We also make the point that although disease prevalence is used to define orphan disease status, a high mortality condition can have a large impact, because it can affect more patients when measured as disease incidence rather than prevalence. Thus, individual cancer cachexia may be considered low prevalence orphan diseases, but higher incidence high impact disorders, a combination of features that should make them very strong candidates for new prevention and treatment development efforts.

Conclusion {#jcsm12402-sec-0013}
==========

We conclude from this analysis that the absolute number of patients affected by cancer cachexia in each cancer group is lower than the defined thresholds in the USA and EU. Hence, cancer cachexia in each subgroup separately should be considered an orphan disease.
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